Reference health
Use of bone turnover markers in postmenopausal osteoporosis
30184-5/badge.svg){kind=icon}
156/156 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 156 checked references that resolve
resolves10.1016/j.bone.2014.05.016
New developments in biological markers of bone metabolism in osteoporosis
resolves10.1007/s00198-015-3095-0
Bone turnover markers in Paget’s disease of the bone: A Systematic review and meta-analysis
resolves10.1007/s00198-008-0660-9
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
resolves10.1007/s00198-010-1501-1
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
resolves10.1359/jbmr.2000.15.7.1398
Biochemical Markers as Predictors of Rates of Bone Loss After Menopause
resolves10.1073/pnas.0805133106
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate
resolves10.1002/jbmr.1862
18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study
resolves10.1210/jc.2015-2957
Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
resolves10.1359/jbmr.1997.12.1.59
Biochemical Markers of Bone Resorption Compared with Estimates of Bone Resorption from Radiotracer Kinetic Studies in Osteoporosis
resolves10.1210/edrv-14-4-424
Molecular Mechanisms Mediating Proliferation/Differentiation Interrelationships During Progressive Development of the Osteoblast Phenotype
resolves10.3892/etm.2014.2071
Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand
resolves10.1016/S8756-3282(00)00248-9
Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy
resolves10.1007/s00198-017-4082-4
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability
resolves10.1002/jbmr.5650050506
Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: A study of sources of variation in assay results
resolves10.1515/CCLM.2011.602
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
resolves10.1016/S8756-3282(02)00728-7
Effect of feeding on bone turnover markers and its impact on biological variability of measurements
resolves10.1016/j.bone.2012.02.003
Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study
resolves10.1515/cclm-2015-0162
Reference intervals for bone turnover markers in Spanish premenopausal women
resolves10.1016/j.bone.2013.09.010
Reference intervals for serum concentrations of three bone turnover markers for men and women
resolves10.1007/s00198-017-4026-z
Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population
resolves10.1016/j.bone.2013.04.003
Age-related reference intervals for bone turnover markers from an Australian reference population
resolves10.1359/jbmr.080703
Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States
resolves10.1002/jbmr.124
Association between bone turnover rate and bone microarchitecture in men: The STRAMBO study
resolves10.1136/ard.2007.077941
High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study
resolves10.1007/s001980050244
Determinants of Bone Loss in Elderly Men and Women: A Prospective Population-Based Study
resolves10.1359/jbmr.090526
Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study
resolves10.1016/j.urolonc.2010.08.007
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
resolves10.1056/NEJMoa0809003
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
resolves10.1359/jbmr.2003.18.1.9
The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis
resolves10.1210/jc.2003-031110
Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
resolves10.1002/jbmr.2407
Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood
resolves10.1210/jc.2013-1047
Abdominal Fat Is Associated With Lower Bone Formation and Inferior Bone Quality in Healthy Premenopausal Women: A Transiliac Bone Biopsy Study
resolves10.1002/jbmr.2564
Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials
resolves10.1249/MSS.0000000000001211
The Effect of Postexercise Carbohydrate and Protein Ingestion on Bone Metabolism
resolves10.1007/s00421-015-3231-8
Effects of soccer vs swim training on bone formation in sedentary middle-aged women
resolves10.1249/MSS.0000000000000320
Calcium Supplementation and Parathyroid Hormone Response to Vigorous Walking in Postmenopausal Women
resolves10.1007/s00198-016-3759-4
Effects of short-term step aerobics exercise on bone metabolism and functional fitness in postmenopausal women with low bone mass
resolves10.1016/j.bone.2015.10.002
Bone metabolism and renal stone risk during International Space Station missions
resolves10.1007/s00198-015-3150-x
Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study
resolves10.1007/s00198-015-3333-5
Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury
resolves10.1007/s00198-014-2734-1
The association between critical illness and changes in bone turnover in adults: a systematic review
resolves10.1007/s00198-015-3032-2
Greater milk intake is associated with lower bone turnover, higher bone density, and higher bone microarchitecture index in a population of elderly Japanese men with relatively low dietary calcium intake: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study
resolves10.1017/S1368980009005084
Low calcium intake is associated with increased bone resorption in postmenopausal Japanese women: Yokogoshi Study
resolves10.1007/s00198-013-2387-5
The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial
resolves10.1017/S0007114509371743
Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women
resolves10.1093/ajcn/67.6.1273
Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake
resolves10.1002/jbmr.2554
Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial
resolves10.1093/ajcn/81.4.923
Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women
resolves10.1038/ejcn.2014.284
Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass
resolves10.1515/CCLM.2009.302
Enhanced bone metabolism in vegetarians – the role of vitamin B12 deficiency
resolves10.1016/j.nutres.2015.12.010
Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism
resolves10.3945/ajcn.110.009605
Association between the Healthy Eating Index and bone turnover markers in US postmenopausal women aged ≥45 y
resolves10.1210/jc.2012-4113
Changes in Bone Resorption Across the Menopause Transition: Effects of Reproductive Hormones, Body Size, and Ethnicity
resolves10.1002/jbmr.2889
Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause
resolves10.1002/jbmr.5650100319
Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis
resolves10.1016/j.maturitas.2006.09.002
Change in serum undercarboxylated osteocalcin concentration in bilaterally oophorectomized women
resolves10.1038/ajg.2014.430
An Association Between Abnormal Bone Turnover, Systemic Inflammation, and Osteoporosis in Patients With Chronic Pancreatitis: A Case-Matched Study
resolves10.1530/EJE-11-0751
Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals
resolves10.1007/s00198-015-3291-y
Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis—results from the TOMORROW study
resolves10.1007/s00198-014-2860-9
Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients
resolves10.1007/s00198-005-2025-y
Changes in bone mass and bone turnover following tibial shaft fracture
resolves10.4081/or.2009.e21
Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
resolves10.1046/j.1532-5415.2001.49177.x
Serum and Urine Markers of Bone Metabolism During the Year After Hip Fracture
resolves10.2174/1874325001105010032
Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
resolves10.1210/jc.2007-1508
Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk
resolves10.1007/s00198-016-3675-7
Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study
resolves10.1359/jbmr.091006
Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years
resolves10.1210/jc.2010-2878
Mineral Metabolism Markers and the Long-Term Risk of Hip Fracture: The Cardiovascular Health Study
resolves10.1007/s00223-014-9842-y
A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
resolves10.1016/j.jocd.2011.05.008
Official Positions for FRAX® Clinical Regarding Biochemical Markers
resolves10.1007/s00198-015-3145-7
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study
resolves10.1002/jbmr.5650110307
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
resolves10.1016/j.jbspin.2011.05.003
Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis
resolves10.1007/s00198-012-2097-4
Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice
resolves10.1016/j.bone.2013.10.006
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
resolves10.1038/ncomms6215
Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
resolves10.1002/jbmr.149
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
resolves10.1007/s00198-014-2646-0
PINP as a biological response marker during teriparatide treatment for osteoporosis
resolves10.1210/jc.2002-021988
Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment
resolves10.1007/s00198-010-1379-y
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
resolves10.1210/jc.2003-1703
Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy
resolves10.1056/NEJM200105103441904
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
resolves10.1002/jbmr.238
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis
resolves10.1359/JBMR.051109
A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide
resolves10.1359/jbmr.040117
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
resolves10.1056/NEJMoa050336
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
resolves10.1359/JBMR.040512
Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial
resolves10.1359/jbmr.07090b
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis
resolves10.1002/jbmr.342
Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence
resolves10.1016/j.clinbiochem.2015.12.002
Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis
resolves10.1007/s00198-011-1583-4
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass
resolves10.1002/jbmr.2442
The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
resolves10.1002/jbmr.2847
Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data
resolves10.1002/jbmr.1644
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
resolves10.1136/ard.62.10.969
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women
resolves10.1111/j.1742-1241.2008.01911.x
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
resolves10.1007/s10354-012-0133-9
Biomarkers of bone turnover in diagnosis and therapy of osteoporosis
resolves10.1007/s00198-017-3906-6
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
resolves10.1210/jc.2003-030501
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
resolves10.1210/jc.2006-1526
Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis
resolves10.1002/jbmr.251
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
resolves10.1016/S2213-8587(17)30138-9
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
resolves10.1210/jc.2010-1502
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
resolves10.1210/jc.2016-3170
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report
resolves10.1210/jc.2013-1402
Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial
resolves10.1007/s00198-015-3174-2
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
resolves10.1016/j.bone.2015.03.002
Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial
resolves10.1210/jc.2016-1801
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
resolves10.1111/j.1365-2796.2004.01317.x
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (<i>EF</i>ficacy of <i>F</i>OSAMAX<sup>®</sup> versus <i>E</i>VISTA<sup>®</sup><i>C</i>omparison <i>T</i>rial) International<sup>1</sup>
resolves10.1007/s00198-016-3573-z
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia
resolves10.1007/s00198-013-2386-6
Adherence to raloxifene therapy: assessment methods and relationship with efficacy
resolves10.1359/jbmr.080710
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
resolves10.1016/j.bone.2009.07.091
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
resolves10.1016/j.bone.2016.05.004
Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment
resolves10.1007/s00198-016-3581-z
A retrospective analysis of nonresponse to daily teriparatide treatment
resolves10.1210/jc.2013-1172
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study
resolves10.1007/s00198-013-2379-5
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
resolves10.1210/jc.2013-4440
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
resolves10.1007/s00198-016-3647-y
Teriparatide and denosumab combination therapy and skeletal metabolism
resolves10.1007/s00774-015-0731-x
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
resolves10.1016/S0140-6736(15)61120-5
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
resolves10.1001/jama.2016.11136
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
resolves10.1002/jbmr.173
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
resolves10.1359/JBMR.051018
Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial
resolves10.1016/j.bone.2006.02.003
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
resolves10.1002/jbmr.2361
Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study
resolves10.2147/TCRM.S123172
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
resolves10.1002/jbmr.2405
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
resolves10.1002/jbmr.1893
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis
resolves10.1002/jbmr.253
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
resolves10.1016/j.bone.2013.07.010
Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy
resolves10.1056/NEJMoa1001086
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
resolves10.1002/jbmr.2708
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
resolves10.1002/jbmr.1494
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
resolves10.1002/jbmr.1864
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
resolves10.1210/jc.2014-1971
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
resolves10.1001/jamainternmed.2014.1232
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy
resolves10.4158/EP.16.S3.1
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis
resolves10.1359/jbmr.060508
Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)
The 6 references without a DOI — listed, not checked
no DOI — not checkedThe microanatomy of trabecular bone loss in normal aging men and women
no DOI — not checkedThe relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa
no DOI — not checkedThe benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
no DOI — not checkedEffect of oral anticoagulant treatment on markers for calcium and bone metabolism
no DOI — not checkedMonitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study
no DOI — not checkedAssociations between systemic markers of bone turnover or bone mineral density and antiresorptive agent-related osteonecrosis of the jaw in patients treated with antiresorptive agents
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s2213-8587(17)30184-5"><img src="https://citestamp.com/citestamped/10.1016/s2213-8587(17)30184-5/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[30184-5/badge.svg)](https://citestamp.com/citestamped/10.1016/s2213-8587(17)30184-5)